“Dupilumab Is a Predominant Treatment for Recalcitrant Bullous Pemphigoid”. Archives of Clinical Case Reports, vol. 4, no. 1, Feb. 2021, pp. 1-4, https://somatopub.com/index.php/ACCR/article/view/17.